Expert Consensus on Gepants for Acute and Preventive Treatment of Migraine in Thailand [PDF]
Journal of Headache and PainIntroduction Gepants, a calcitonin gene-related peptide (CGRP) receptor antagonist, is a class of migraine therapeutic options with extensive evidence supporting a favorable efficacy and safety profile. However, as a novel class of medication in Thailand,
Surat Tanprawate, Pannathat Soontrapa
exaly +6 more sources
Gepants: Targeting the CGRP Pathway for Migraine Relief [PDF]
Frontiers in PharmacologyBackgroundCalcitonin gene–related peptide (CGRP) receptor antagonist (collectively known as gepant) have emerged as effective therapies for both acute migraine treatment and preventive management.
Magdalena Sowa-Kućma
exaly +6 more sources
Gepants in Primary Care: A Targeted Approach to Acute and Preventive Treatment of Migraine [PDF]
Pain and TherapyWith 80% of migraines diagnosed and managed by primary care clinicians, a knowledge of standard of care and novel therapy is essential for those caring for people with this chronic disease. This review describes a new class of medication, calcitonin gene-
Maureen A. Moriarty, Carol A. Barch
exaly +5 more sources
Gepants for Abortive Treatment of Migraine: A Network Meta-Analysis [PDF]
Brain and Behavior, 2020 Objectives To evaluate and compare the efficacy and safety of gepants for abortive treatment of migraine by network meta‐analysis. Materials & Methods Publications, which were randomized controlled trials (RCTs) about gepants for abortive treatment of ...
Peiwei Hong, Jing Xiao
exaly +4 more sources
Adverse Events Associated With Gepants: A Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System [PDF]
Journal of Headache and PainBackground Gepants have demonstrated notable benefits in migraine therapy, yet their safety profiles are not thoroughly investigated. This study comprehensively analyzed the adverse event (AE) risk signals of the currently approved gepants using the U.S.
Yaqian Tan
exaly +3 more sources
Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment [PDF]
MedCommMigraine is a common, disabling brain disorder that affects about 1 billion people worldwide and disproportionately burdens women and working‐age adults.
Weiwei Lu +9 more
doaj +3 more sources
Delphi consensus on the real-world application of the updated diagnostic and treatment guidelines for migraine in Asia Pacific [PDF]
Frontiers in NeurologyBackgroundAlthough diagnostic criteria and treatment guidelines for migraine are well-established, care remains suboptimal due to frequent misdiagnosis and undertreatment.
Charles Hua Chiang Siow +17 more
doaj +2 more sources
Pharmaceutics, 2020 In the last few years, there have been significant advances in migraine management and prevention. Lasmiditan, ubrogepant, rimegepant and monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) are new drugs that were launched on ...
Danuta Szkutnik-Fiedler
exaly +3 more sources
CGRP-Targeting Therapies in Vestibular Migraine: A Synthesis of Observational Evidence with Direction-of-Effect Analysis [PDF]
Medical SciencesBackground: Vestibular migraine (VM) is a common but underdiagnosed cause of episodic vertigo lacking evidence-based preventive treatments. Calcitonin gene-related peptide (CGRP) plays a central role in migraine pathogenesis and is expressed in ...
Alin Ciubotaru +13 more
doaj +2 more sources
Neurology and TherapyIntroduction The introduction of clacitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) has revolutionized the treatment of migraines. In clinical practice gepants might be considered as a valid option to treat acute attacks in patients with
Taoufik Alsaadi, Reem S
exaly +2 more sources